Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular carcinoma

Journal of Enzyme Inhibition and Medicinal Chemistry
Bassam M AyoubMahmoud Salama Ahmed

Abstract

Chemical entities with structural diversity were introduced as candidates targeting adenosine receptor with different clinical activities, containing 3,7-dihydro-1H-purine-2,6-dione, especially adenosine 3 receptors (ADORA3). Our initial approach started with pharmacophore screening of ADORA3 modulators; to choose linagliptin (LIN), approved anti-diabetic drug as Dipeptidyl peptidase-4 inhibitors, to be studied for its modulating effect towards ADORA3. This was followed by generation, purification, analytical method development, and structural elucidation of oxidative degraded product (DEG). Both of LIN and DEG showed inhibitory profile against hepatocellular carcinoma cell lines with induction of apoptosis at G2/M phase with increase in caspase-3 levels, accompanied by a downregulation in gene and protein expression levels of ADORA3 with a subsequent increase in cAMP. Quantitative in vitro assessment of LIN binding affinity against ADORA3 was also performed to exhibit inhibitory profile at Ki of 37.7 nM. In silico molecular modelling showing binding affinity of LIN and DEG towards ADORA3 was conducted.

References

Mar 27, 2001·Annual Review of Pharmacology and Toxicology·J Linden
May 9, 2001·The Journal of Pharmacy and Pharmacology·Y HigashiA Tsuji
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Sep 5, 2002·Nature Reviews. Molecular Cell Biology·Kristen L PierceRobert J Lefkowitz
Oct 19, 2005·Journal of Virological Methods·Søren GroveBirgit Helene Dannevig
Jun 19, 2008·Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·J Saltyte BenthS Mitic
Jul 30, 2009·Handbook of Experimental Pharmacology·Kenneth A Jacobson
Jul 30, 2009·Handbook of Experimental Pharmacology·S Jamal MustafaAmir Pelleg
Jul 20, 2010·Neuropharmacology·Vsevolod KatritchRuben Abagyan
Dec 28, 2010·Biochimica Et Biophysica Acta·Christa E Müller, Kenneth A Jacobson
Dec 29, 2010·Journal of Medicinal Chemistry·Vicente YazijiEddy Sotelo
Oct 29, 2011·Drug Discovery Today·Pnina FishmanKenneth A Jacobson
Mar 1, 2012·Acta Pharmacologica Sinica·Xiao-long TangMing-yao Liu
Mar 29, 2013·Nature Reviews. Drug Discovery·Jiang-Fan ChenBertil B Fredholm
Mar 30, 2016·Current Opinion in Nephrology and Hypertension·Harold M Szerlip, Lakhmir S Chawla
Mar 14, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Antonella Ciancetta, Kenneth A Jacobson

❮ Previous
Next ❯

Citations

Mar 21, 2020·Frontiers in Pharmacology·Yong LiZhenxiao Sun
Jul 25, 2019·Current Pharmaceutical Design·Sarapynbiang MarweinPratap C Acharya

❮ Previous
Next ❯

Methods Mentioned

BETA
column chromatography
NMR
ELISA
PCR

Software Mentioned

3D
Openeye
GraphPad Prism
Scan
MMFF94

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.